When was Entrada Therapeutics founded?

Entrada Therapeutics was founded in 2016.

Where is Entrada Therapeutics located?

Entrada Therapeutics is headquartered in Boston, United States.

How many employees does Entrada Therapeutics have?

As of Aug 31, 2026, the latest employee count at Entrada Therapeutics is 203.

Is Entrada Therapeutics a funded company?

Entrada Therapeutics is a funded company, having raised a total of $175M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of Entrada Therapeutics?

Entrada Therapeutics' latest funding was a $***** Series B round on Mar 31, 2021, with participation from 12 investors. Its primary sector is Rare Diseases. In United States, the Rare Diseases sector has seen $919M in funding in 2026 to date.

What is the annual revenue of Entrada Therapeutics?

Annual revenue of Entrada Therapeutics is between $10M and $50M as on Dec 31, 2025

Where does Entrada Therapeutics rank among its competitors?

Entrada Therapeutics ranks 39th amongst 297 active competitors, of which 84 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Entrada Therapeutics?

Entrada Therapeutics' top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, BridgeBio secured the most recent funding round in April, 2024.

Entrada Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Entrada Therapeutics is a public company based in Boston (United States), founded in 2016 by Dehua Pei. It operates as a Developer of the biologics-based platform to treat rare diseases. Entrada Therapeutics has raised $175M in funding from investors like 5AM Ventures, Wellington and MRLV. The company has 297 active competitors, including 84 funded and 100 that have exited. Its top competitors include companies like BridgeBio, Alnylam and PTC Therapeutics.

Company Details

Developer of the biologics-based platform to treat rare diseases. It has a proprietary intracellular biologics platform which enables intracellular delivery of biologics (proteins, peptides, and nucleic acids). It offers a pipeline of candidates which include ENTR-601-44 Duchenne Muscular Dystrophy, and VX-670 for Myotonic Dystrophy Type 1. It also provide drugs for immunology and ocular indications.

Website: www.entradatx.com/
Email ID: *****@entradatx.com

Key Metrics

Founded Year

2016

Location

Boston, United States

Stage

Public

Total Funding

$175M in 3 rounds

Latest Funding Round

Series B, Mar 31, 2021, $*****

Investors

5AM Ventures & 12 more

Ranked

39^th among 297 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2025

Employee Count

203 as on Aug 31, 2026

Similar Companies

BridgeBio & 332 more

Exit Details

Public

View Entrada Therapeutics' full profile

Entrada Therapeutics is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Entrada Therapeutics, Inc. CIN: 20211538086 , United States, Active	Jun 08, 2021	-	-	-
Entrada Therapeutics, Inc. CIN: 1689375 , United States, Active	Sep 21, 2016	$10M - $50M (As on Dec 31, 2025)	-	-
Entrada Therapeutics, Inc. CIN: 81-3983399 , United States, Active	Sep 21, 2016	-	122 (As on Dec 31, 2022)	-

Entrada Therapeutics got listed on Oct 29, 2021.

Click here to take a look at Entrada Therapeutics's IPO in detail

Entrada Therapeutics has raised a total funding of $175M over 3 rounds. Its latest funding round was a Series B round on Mar 31, 2021 for $*****. 12 investors participated in its latest round. Entrada Therapeutics has 13 institutional investors.

Here is the list of recent funding rounds of Entrada Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 31, 2021	8715839	Series B	8821450	2281579	2782365	6413944
Dec 22, 2018	1731843	Series A	5577837	3597182	5AM Ventures	Roche & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Entrada Therapeutics's funding rounds and investors

The founders of Entrada Therapeutics is Dehua Pei. Dipal Doshi is the CEO of Entrada Therapeutics.

Here are the details of Entrada Therapeutics' key team members:

Dehua Pei: Former Co-Founder of Entrada Therapeutics.

View details of Entrada Therapeutics's Founder profiles and Board Members

Entrada Therapeutics' employee count trend

Entrada Therapeutics has 203 employees as of Aug 26. Here is Entrada Therapeutics's employee count trend over the years:

Employee count trend for Entrada Therapeutics

Uncover Entrada Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Entrada Therapeutics include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Entrada Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	80/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
6th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
7th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
8th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
9th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
10th	Ionis 1989, United States, Public	Developer of RNA-targeted medicines for various diseases	-	BB Biotech, Ojp & 1 others	67/100
39th	Entrada Therapeutics 2016, Boston (United States), Public	Developer of the biologics-based platform to treat rare diseases	$175M	Goldman Sachs, Point72 & 11 others	59/100